PanGen Biotech Inc. (KOSDAQ:222110)

PanGen Biotech Statistics

Total Valuation

PanGen Biotech has a market cap or net worth of KRW 77.19 billion. The enterprise value is 64.88 billion.

Market Cap	77.19B
Enterprise Value	64.88B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

PanGen Biotech has 13.49 million shares outstanding. The number of shares has increased by 16.89% in one year.

Current Share Class	13.49M
Shares Outstanding	13.49M
Shares Change (YoY)	+16.89%
Shares Change (QoQ)	+10.17%
Owned by Insiders (%)	4.06%
Owned by Institutions (%)	n/a
Float	6.36M

Valuation Ratios

The trailing PE ratio is 45.13.

PE Ratio	45.13
Forward PE	n/a
PS Ratio	5.05
PB Ratio	2.57
P/TBV Ratio	2.65
P/FCF Ratio	n/a
P/OCF Ratio	252.33
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.97, with an EV/FCF ratio of -148.19.

EV / Earnings	39.54
EV / Sales	4.25
EV / EBITDA	20.97
EV / EBIT	39.74
EV / FCF	-148.19

Financial Position

The company has a current ratio of 8.52, with a Debt / Equity ratio of 0.03.

Current Ratio	8.52
Quick Ratio	5.68
Debt / Equity	0.03
Debt / EBITDA	0.30
Debt / FCF	-2.11
Interest Coverage	9.99

Financial Efficiency

Return on equity (ROE) is 6.83% and return on invested capital (ROIC) is 3.98%.

Return on Equity (ROE)	6.83%
Return on Assets (ROA)	3.51%
Return on Invested Capital (ROIC)	3.98%
Return on Capital Employed (ROCE)	5.44%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.53
Inventory Turnover	1.46

Taxes

In the past 12 months, PanGen Biotech has paid 76.44 million in taxes.

Income Tax	76.44M
Effective Tax Rate	4.45%

Stock Price Statistics

The stock price has decreased by -12.50% in the last 52 weeks. The beta is -0.13, so PanGen Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.13
52-Week Price Change	-12.50%
50-Day Moving Average	6,029.60
200-Day Moving Average	5,782.83
Relative Strength Index (RSI)	41.90
Average Volume (20 Days)	20,570

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PanGen Biotech had revenue of KRW 15.27 billion and earned 1.64 billion in profits. Earnings per share was 126.74.

Revenue	15.27B
Gross Profit	5.08B
Operating Income	1.63B
Pretax Income	1.72B
Net Income	1.64B
EBITDA	3.09B
EBIT	1.63B
Earnings Per Share (EPS)	126.74

Balance Sheet

The company has 13.23 billion in cash and 923.89 million in debt, giving a net cash position of 12.31 billion or 912.21 per share.

Cash & Cash Equivalents	13.23B
Total Debt	923.89M
Net Cash	12.31B
Net Cash Per Share	912.21
Equity (Book Value)	30.03B
Book Value Per Share	2,201.42
Working Capital	20.60B

Cash Flow

In the last 12 months, operating cash flow was 305.89 million and capital expenditures -743.69 million, giving a free cash flow of -437.80 million.

Operating Cash Flow	305.89M
Capital Expenditures	-743.69M
Free Cash Flow	-437.80M
FCF Per Share	-32.44

Margins

Gross margin is 33.23%, with operating and profit margins of 10.69% and 10.74%.

Gross Margin	33.23%
Operating Margin	10.69%
Pretax Margin	11.24%
Profit Margin	10.74%
EBITDA Margin	20.25%
EBIT Margin	10.69%
FCF Margin	n/a

Dividends & Yields

PanGen Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.89%
Shareholder Yield	-16.89%
Earnings Yield	2.13%
FCF Yield	-0.57%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PanGen Biotech has an Altman Z-Score of 17.86 and a Piotroski F-Score of 4.

Altman Z-Score	17.86
Piotroski F-Score	4